EUVIMEDEUVIMED entdecken
Vergleichsstudie

Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST

Yueling Deng, Xiao Zhang, Fan Hu, Xiaoli Lan iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07342-8 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Yueling Deng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to evaluate the predictive value of 18F-FDG PET/CT for pathological complete response (pCR) after neoadjuvant immunochemotherapy in resectable non-small cell lung cancer (NSCLC) and develop a quantitative pCR prediction model. We compared the model's performance with RECIST 1.1 and PERCIST. METHOD: A retrospective review was conducted on patients with resectable NSCLC who received neoadjuvant immunochemotherapy from January 2020 to December 2023. Patients with both pre-treatment (18F-FDG PET/CT scan-1) and preoperative scans (18F-FDG PET/CT scan-2) were included. 18F-FDG PET/CT parameters, clinical characteristics, and follow-up data were collected. Logistic regression was used to identify independent predictors and construct the prediction model. The model's predictive performance was compared with RECIST 1.1 and PERCIST criteria. The model was validated with an external cohort from January to September 2024. Postoperative pathological results serve as the gold standard for pCR. RESULTS: 36 patients were included for model development, with 19 (52.8%) achieving pCR. ΔTLR% (percentage change between two scans in tumor-to-liver ratio) and SULpeak from scan-2 were significant predictors. The developed prediction model demonstrated outstanding performance with an area under the curve (AUC) of 0.975, 100% sensitivity, and 94.1% specificity. In comparison, RECIST 1.1 showed poor sensitivity (10.5%) but high specificity (100%), while PERCIST had moderate sensitivity (73.7%) and specificity (94.1%). Validation with 8 patients confirmed the model's accuracy. CONCLUSIONS: This study suggests that 18F-FDG PET/CT, specifically the ΔTLR% and SULpeak from scan-2, is a reliable predictor of pCR in resectable NSCLC undergoing neoadjuvant immunochemotherapy. The quantitative prediction model outperforms both RECIST 1.1 and PERCIST. These findings highlight the potential clinical utility of this model, although further validation with larger cohorts is required to confirm its robustness and generalizability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18Lung NeoplasmsNeoadjuvant TherapyResponse Evaluation Criteria in Solid TumorsImmunotherapyHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTreatment Outcome

Stichwörter der Autor:innen

18F-FDG PET/CTNeoadjuvant immunochemotherapyNon-small cell lung cancerPathological complete response

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
  • Key Laboratory of Biological Targeted Therapy of the Ministry of Education, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.
  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. LXL730724@hotmail.com.
  • Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China. LXL730724@hotmail.com.
  • Key Laboratory of Biological Targeted Therapy of the Ministry of Education, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China. LXL730724@hotmail.com.

ORCID-Profile: Xiaoli Lan

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Deng, Y., Zhang, X., Hu, F., & Lan, X. (2025). Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07342-8

Vancouver

Deng Y, Zhang X, Hu F, Lan X. Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07342-8

BibTeX
@article{Deng2025,
  author = {Deng, Yueling and Zhang, Xiao and Hu, Fan and Lan, Xiaoli},
  title = {Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07342-8}
}
Kostenlos starten →